Home » UK Drug Body Backs Thalidomide, Velcade in Multiple Myeloma
UK Drug Body Backs Thalidomide, Velcade in Multiple Myeloma
The UK’s health-care cost-effectiveness body Wednesday backed publicly funded use of Celgene Corp.’s thalidomide and Johnson & Johnson’s bortezomib on the National Health Service for treating a type of bone marrow cancer called multiple myeloma.
The Wall Street Journal
The Wall Street Journal
Upcoming Events
-
14May
-
23May
-
30May
-
20Jun
-
21Oct